CDMO VGXI will increase plasmid DNA capacity by over 500% through an investment at a site in Conroe, Texas. The contract development manufacturing organization (CDMO) did not divulge any financial details associated with its new headquarters and manufacturing plant. However, the facility will be located at Deison Technology Park in Conroe, Texas on a 21.5-acre area of land. “The new facility is purpose built to support VGXI’s optimized Plasmid DNA production process at expanded scales and across multiple flexible manufacturing…

CDMO Catalent has invested to expand cryogenic capabilities at its clinical supply services facility in Philadelphia to meet cell and gene therapy demand. The contract development manufacturing organization (CDMO) did not disclose any financial details of the investment. However, a spokesperson for Catalent told BioProcess Insider “In addition to the equipment necessary to handle, package and label cryogenic materials, Catalent will add five cryogenic freezers with enough capacity for tens of thousands of vials at very low temperatures of around…

Albumedix has completed expansion of its commercial-scale manufacturing facility and established new labs, doubling its albumin production capacity. After more than three years of design and construction work, Albumedix has completed the expansion of its Nottingham facility and is now able to manufacture out of this site. The expansion enables the firm to more than double its albumin production, which is used for stabilization and to deliver pharmaceuticals. “Part of the expansion included the construction of a four-storey building adjacent…

Abzena has selected Sanford, North Carolina as the site of a biologics manufacturing facility equipped with 12x 2,000 L bioreactors. In January, British contract development manufacturing organization (CDMO) Abzena announced the addition of a sixth global site in the US. The exact location of the plant was not divulged. However, the firm revealed this week that the site will be in Sanford, North Carolina. The Sanford facility will cost over $200 million and will be dedicated to manufacturing mammalian biologics.…

CDMO Catalent has completed an $85 million expansion at its Madison drug substance facility and has started work on customer programs. The contract development manufacturing organization (CDMO) Catalent has added two mammalian cell culture suites at its Madison facility, meaning the site has five suites in total and has more than doubled its overall capacity. The two additional suites each boast a 2 x 2,000 L single-use bioreactor system that can process batches of 2,000 L or 4,000 L for…